A5001330237- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- Economic and Financial Impacts of Cancer
- CAR-T cell therapy research
- Bladder and Urothelial Cancer Treatments
- Melanoma and MAPK Pathways
- Cutaneous Melanoma Detection and Management
- Health Systems, Economic Evaluations, Quality of Life
- Multiple and Secondary Primary Cancers
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Eosinophilic Disorders and Syndromes
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Ferroptosis and cancer prognosis
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Venous Thromboembolism Diagnosis and Management
- Breast Cancer Treatment Studies
- Acute Myocardial Infarction Research
- Mental Health Research Topics
- Atrial Fibrillation Management and Outcomes
- Chemotherapy-induced cardiotoxicity and mitigation
- Digital Mental Health Interventions
Gilead Sciences (United States)
2023-2024
Bristol-Myers Squibb (United States)
2017-2022
Background Treatment-free survival (TFS) characterizes disease control after discontinuation of immune checkpoint inhibitors (ICIs) until subsequent therapy or death. We previously evaluated TFS in a pooled analysis the CheckMate 067 and 069 trials ICIs nivolumab ipilimumab, alone combination, patients with advanced melanoma minimum follow-up 36 months. This investigated differences between treatments 60 months, their relation to overall (OS) differences. Methods Data were from 937 who...
Abstract Purpose: Patients discontinuing immuno-oncology regimens may experience periods of disease control without need for ongoing anticancer therapy, but toxicity persist. We describe treatment-free survival (TFS), with and toxicity. Methods: Data were analyzed from the randomized phase III CheckMate 214 trial nivolumab plus ipilimumab (n = 550) versus sunitinib 546) treatment-naïve, advanced renal cell carcinoma (aRCC). TFS was estimated by 42-month restricted mean times defined area...
Abstract Low molecular weight heparins (LMWHs) and direct oral anticoagulants (DOACs) are among the recommended treatment options for cancer-associated thrombosis (CAT) in 2019 National Comprehensive Care Network guidelines. Little is known about current utilization of DOACs CAT patients, particularly on inpatient to outpatient therapy transition. This study assessed real-world patterns hospital/ED adult cancer patients (≥ 18 years) diagnosed with during a hospital visit IQVIA’s Hospital...
Abstract Background Recurrence-free survival (RFS) and overall (OS) data for adjuvant nivolumab versus placebo (proxy routine surveillance) in patients with high-risk, resected melanoma are lacking. This post hoc, indirect treatment comparison (ITC) used pooled from the phase 3 EORTC 18,071 (ipilimumab vs. placebo) CheckMate 238 (nivolumab ipilimumab) trials to assess RFS OS numbers needed treat (NNT) over 4 years. Methods Patients stage IIIB-C cutaneous (American Joint Committee on Cancer...
Abstract Purpose Patients with metastatic triple-negative breast cancer (mTNBC) have poor prognosis and limited treatment options. Sacituzumab govitecan (SG), a Trop-2–directed antibody–drug conjugate, is approved for patients mTNBC who received ≥ 2 systemic therapies (≥ 1 in the setting) based on ASCENT study (NCT02574455). The current describes real-world SG use outcomes United States. Methods This retrospective, observational included adult from ConcertAI Patient360™ database second line...
Purpose To evaluate treatment patterns in patients diagnosed with incident chronic myelogenous leukemia (CML) newly initiating therapy imatinib, dasatinib, or nilotinib. Patients were followed to determine switching and discontinuation rates. Factors associated from index TKI therapy, reasons for based on electronic chart notes, frequency of laboratory monitoring assessed during the follow-up period. Methods A retrospective cohort study was conducted aged ≥ 18 years who identified Kaiser...
305 Background: Nivolumab plus ipilimumab (NIVO+IPI), a first-in-class combination immunotherapy, was approved by the US Food and Drug Administration in April 2018 for treatment of intermediate- or poor-risk advanced renal cell carcinoma (RCC), paradigm has changed dramatically over past few years. This real-world study examined patterns sequences, response, safety, survival outcomes with this novel first-line (1L) therapy among patients diagnosed metastatic RCC (mRCC) community oncology...
Patients with advanced melanoma treated immune checkpoint inhibitors can experience ongoing disease control after treatment discontinuation without subsequent systemic anticancer therapy. We previously defined a novel outcome, treatment-free survival (TFS), as the time between protocol therapy cessation and initiation/death. assessed effect of established prognostic variables [lactate dehydrogenase (LDH), programmed death ligand 1 status, BRAF mutation performance sex] on TFS in different...
<h3>Background</h3> Nivolumab is approved in the US and EU for adjuvant treatment of resected stage III-IV melanoma based on results from CheckMate-238 clinical trial.<sup>1,2</sup> However, trial did not enroll any patients with Stage IIIA disease per American Joint Committee Cancer (AJCC) 7th edition criteria included a limited number AJCC 8th edition.<sup>3,4,5</sup>Recognizing need real-world data to assess outcomes treated nivolumab, non-interventional study was conducted investigate...
286 Background: RCC accounts for ~80%‒90% of all kidney cancers worldwide. The mRCC treatment landscape is rapidly changing with the approval new therapies; data describing real-world (RW) patterns and sequencing are limited. This study investigates characteristics, patterns, patients in RW (December 2015‒May 2020) post-dual immuno-oncology therapy (IO-IO) United States (April 2018‒May 2020). Methods: Adults diagnosed between December 2015 May 2020 were selected from Flatiron electronic...
Adherence to adjuvant therapy is crucial for effective disease management in patients with resected melanoma. This study assessed patient-reported adherence and identified behavioral/belief constructs associated Patients stage III/IV melanoma were recruited through the Melanoma Research Foundation a patient panel complete an online survey. Patient characteristics, medical history, captured. In accordance theory of planned behavior (TPB), survey measured behavioral, normative, control...
288 Background: The introduction of second-line (2L) nivolumab (NIVO) in 2015 (CheckMate 025) and first-line (1L) NIVO plus ipilimumab (NIVO+IPI) 2018 214) revolutionized the management mRCC US. This study sought to leverage real-world (RW) data by applying CheckMate 214 inclusion criteria develop a RW comparator for trial assess treatment patterns sequences patients (pts) with after receiving 1L NIVO+IPI or sunitinib (SUN). Methods: retrospective identified pts clear cell from Flatiron...
4578 Background: Nivolumab in combination with cabozantinib (N+C) has demonstrated significantly improved progression-free survival (PFS), objective response rate (ORR), and overall (OS), compared sunitinib as a first-line (1L) treatment for aRCC the phase 3 CheckMate (CM) 9ER trial. As there are no head-to-head trials comparing N+C pembrolizumab axitinib (P+A), this study efficacy of P+A 1L aRCC. Methods: An MAIC was conducted using individual patient data on (N = 323) from CM trial (median...
4538 Background: Knowledge of large-scale real-world treatment patterns and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) is limited. We conducted this study to address the lack knowledge identify unmet needs pts mUC practice. Methods: The US nationwide Flatiron Health electronic health records–derived, de-identified database, comprised 280 oncology practices across US, was utilized conduct a retrospective cohort analysis diagnosed between Jan 1, 2011, Aug...
Supplementary Data from Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
<div>AbstractPurpose:<p>Patients discontinuing immuno-oncology regimens may experience periods of disease control without need for ongoing anticancer therapy, but toxicity persist. We describe treatment-free survival (TFS), with and toxicity.</p>Patients Methods:<p>Data were analyzed from the randomized phase III CheckMate 214 trial nivolumab plus ipilimumab (<i>n</i> = 550) versus sunitinib 546) treatment-naïve, advanced renal cell carcinoma (aRCC). TFS...
<div>AbstractPurpose:<p>Patients discontinuing immuno-oncology regimens may experience periods of disease control without need for ongoing anticancer therapy, but toxicity persist. We describe treatment-free survival (TFS), with and toxicity.</p>Patients Methods:<p>Data were analyzed from the randomized phase III CheckMate 214 trial nivolumab plus ipilimumab (<i>n</i> = 550) versus sunitinib 546) treatment-naïve, advanced renal cell carcinoma (aRCC). TFS...
Supplementary Data from Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial